BILLERICA, Massachusetts—July 14, 2010 —Millipore Corporation, a leading provider of technologies, tools and services for the global life science industry, jointly announced with BioOutsource Ltd. that they have formed a strategic alliance. The industry knowledge, scientific strength and modern facilities of the two companies combine to offer a world-class biosafety testing partner that biopharmacetical manufacturers can rely on as an extension of their own quality assurance teams. This collaboration will enable Millipore and BioOutsource to bring a full range of biosafety services to industrial clients who seek a world-class supplier.
The criticality of release testing for vaccine and biological products can create challenges for biopharmaceutical and pharmaceutical organizations, which, in turn, can lead to delays in product development and release. Through the combination of Millipore’s state-of-the-art cGMP facility in Leiden, The Netherlands, and BioOutsource’s custom-built cGMP facility in Glasgow, U.K., biopharmaceutical manufacturers can feel confident that their drug products will be produced safely and successfully.
“This alliance offers manufacturers a new alternative for contract testing which will allow them to deploy their resources in other critical areas. For example, these resources can be re-focused on drug development or manufacturing and ultimately reduce a product’s time to market. The complementary nature of both companies’ offerings means customers can benefit from a best-in-class biosafety portfolio, with technical and scientific strength second to none,” says Andrew Bulpin, Ph.D., Millipore’s Vice President, Services and Solutions and Upstream Processing.
“This new joint offering is comprehensive, providing scientific expertise and proven industry experience. Our goals are to help the industry reduce time spent on the development process as well as provide a reliable resource for product release testing to specification within a cGMP environment. This can also lower the necessity of a company maintaining its own cGMP quality control facility within its organization, thus decreasing overall costs dramatically,” says Gerry MacKay, Chief Executive Officer, BioOutsource.
About Millipore
Millipore (NYSE: MIL) is a Life Science leader providing cutting-edge technologies, tools, and services for bioscience research and biopharmaceutical manufacturing. As a strategic partner, we collaborate with customers to confront the world’s challenging human health issues. From research to development to production, our scientific expertise and innovative solutions help customers tackle their most complex problems and achieve their goals. Millipore Corporation is an S&P 500 company with more than 6000 employees worldwide. For more information, visit http://www.millipore.com.
ADVANCING LIFE SCIENCE TOGETHER® Research. Development. Production.
About BioOutsource
BioOutsource is a Contract Testing Organisation (CTO) serving the global Biotechnology Industry. The company provides cGMP testing in areas of biosafety and product characterization as well as regulatory and consultancy services. The company was formed in 2007 and has quickly established a global customer base with a strong empahasis on delivering excellent customer service and rapid turnaround times in testing. For more information, visit www.biooutsource.com.
Millipore Media Contact: Karen Marinella Hall Director of Corporate Communications Millipore Corporation 978-715-1567 karen_hall@millipore.com
Investors: Joshua Young Director, Investor Relations 978-715-1527 joshua_young@millipore.com
